Benjamin F. Edwards & Company, Inc. Histogen Inc. Call Options Transaction History

Benjamin F. Edwards & Company, Inc.

  • $5.69 Billion
  • Q2 2024

Call Options

0 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
No transaction found.

Others Institutions Holding HSTO

# of Institutions
1
Shares Held
17
Call Options Held
0
Put Options Held
0
View Full List

About Histogen Inc.

HSTO Quotes by TradingView
  • Ticker HSTO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,497,450
  • Market Cap $49.9K
  • Description
  • Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media...
More about HSTO
Track This Portfolio

Track Benjamin F. Edwards & Company, Inc. Portfolio

Follow Benjamin F. Edwards & Company, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Benjamin F. Edwards & Company, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Benjamin F. Edwards & Company, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email